{"id":"car-t-cd19","safety":{"commonSideEffects":[{"rate":"null","effect":"Cytokine release syndrome"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CAR-T cells are genetically modified to express a chimeric antigen receptor that recognizes and binds to CD19 on the surface of B cells, leading to their destruction.","oneSentence":"Chimeric antigen receptor T-cell therapy targeting CD19","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:12.569Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell lymphomas"}]},"trialDetails":[{"nctId":"NCT05702853","phase":"PHASE1, PHASE2","title":"Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-11-06","conditions":"B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":27},{"nctId":"NCT06154252","phase":"PHASE2, PHASE3","title":"RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2023-12-20","conditions":"Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome","enrollment":74},{"nctId":"NCT04531046","phase":"PHASE2","title":"Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-03-10","conditions":"B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent","enrollment":62},{"nctId":"NCT01087294","phase":"PHASE1","title":"Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-08-04","conditions":"Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins","enrollment":85},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT05674175","phase":"PHASE1, PHASE2","title":"Co-administration of CART22-65s and huCART19 for B-ALL","status":"RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2023-01-25","conditions":"B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma","enrollment":93},{"nctId":"NCT07328503","phase":"PHASE2","title":"CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Acute Lymphoblastic Leukemia, B-All","enrollment":20},{"nctId":"NCT07371403","phase":"NA","title":"MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"King Hussein Cancer Center","startDate":"2026-02","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia Refractory","enrollment":12},{"nctId":"NCT06847269","phase":"PHASE2","title":"CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-05-21","conditions":"Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia","enrollment":25},{"nctId":"NCT05826535","phase":"PHASE1, PHASE2","title":"Study of LYL314 in Aggressive Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Lyell Immunopharma, Inc.","startDate":"2023-05-09","conditions":"Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma","enrollment":270},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT07493395","phase":"PHASE2","title":"Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-04-01","conditions":"Scleroderma, Systemic","enrollment":6},{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT05514327","phase":"NA","title":"A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-09-01","conditions":"Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy","enrollment":20},{"nctId":"NCT07491263","phase":"PHASE1","title":"Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2026-05-01","conditions":"Relapsed/Refractory CD19-positive B-ALL","enrollment":6},{"nctId":"NCT07250269","phase":"PHASE1","title":"Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis","status":"RECRUITING","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","startDate":"2025-10-29","conditions":"Relapsed/Refractory AL Amyloidosis","enrollment":9},{"nctId":"NCT07490951","phase":"NA","title":"Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Genocury Biotech Co., Ltd.","startDate":"2026-03-22","conditions":"Autoimmune Diseases","enrollment":20},{"nctId":"NCT07081646","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-08-18","conditions":"Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis","enrollment":91},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT07003295","phase":"PHASE2","title":"Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-14","conditions":"Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":20},{"nctId":"NCT06150651","phase":"PHASE1","title":"Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2023-12-01","conditions":"SLE (Systemic Lupus)","enrollment":3},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Non-Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT05359211","phase":"PHASE1","title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-08","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":27},{"nctId":"NCT07478848","phase":"PHASE1","title":"Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2026-04-07","conditions":"Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL), Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":14},{"nctId":"NCT07479797","phase":"PHASE3","title":"Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2026-08","conditions":"Relapsed or Refractory Large B-cell Lymphoma (r/r LBCL)","enrollment":550},{"nctId":"NCT02601313","phase":"PHASE2","title":"Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-11-09","conditions":"Relapsed/Refractory Mantle Cell Lymphoma","enrollment":105},{"nctId":"NCT06500273","phase":"PHASE2","title":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","status":"RECRUITING","sponsor":"Allogene Therapeutics","startDate":"2024-06-18","conditions":"Large B-cell Lymphoma","enrollment":250},{"nctId":"NCT04889716","phase":"PHASE2","title":"CAR-T Followed by Bispecific Antibodies","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-11-05","conditions":"Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":42},{"nctId":"NCT04119024","phase":"PHASE1","title":"Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Anusha Kalbasi","startDate":"2025-10-07","conditions":"Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":18},{"nctId":"NCT03455972","phase":"PHASE1, PHASE2","title":"Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2018-02-20","conditions":"Safety and Efficacy","enrollment":43},{"nctId":"NCT07015983","phase":"PHASE2","title":"A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-07-14","conditions":"Lupus Erythematosus, Systemic, Lupus Nephritis","enrollment":89},{"nctId":"NCT06026319","phase":"PHASE1","title":"CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2023-10-26","conditions":"Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT07038447","phase":"PHASE1","title":"A Study of KITE-363 in Participants With Refractory Autoimmune Diseases","status":"ENROLLING_BY_INVITATION","sponsor":"Kite, A Gilead Company","startDate":"2025-07-02","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis","enrollment":52},{"nctId":"NCT07472972","phase":"","title":"Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2025-06-20","conditions":"Lymphoma, Lymphoid Hematological Malignancies","enrollment":50},{"nctId":"NCT06561425","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Galapagos NV","startDate":"2022-03-09","conditions":"Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell","enrollment":130},{"nctId":"NCT07137494","phase":"PHASE1","title":"A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-08-14","conditions":"Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma","enrollment":12},{"nctId":"NCT07473154","phase":"PHASE1, PHASE2","title":"Controlling Hyperactive Immunity With Long-lived Lymphocytes","status":"NOT_YET_RECRUITING","sponsor":"Quell Therapeutics Limited","startDate":"2026-04","conditions":"Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)","enrollment":16},{"nctId":"NCT06481735","phase":"PHASE1, PHASE2","title":"TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-02-15","conditions":"Acute Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT07473167","phase":"PHASE1, PHASE2","title":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","status":"RECRUITING","sponsor":"TICAROS Co., Ltd.","startDate":"2023-08-03","conditions":"Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":98},{"nctId":"NCT06711146","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2024-12-24","conditions":"Systemic Lupus Erythematosus","enrollment":36},{"nctId":"NCT07470073","phase":"EARLY_PHASE1","title":"A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-04-01","conditions":"ALL (Acute B-Lymphoblastic Leukemia)","enrollment":18},{"nctId":"NCT07463781","phase":"","title":"Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2026-05","conditions":"Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma, Primary Mediastinal B-cell Lymphoma (PMBCL)","enrollment":100},{"nctId":"NCT05421663","phase":"PHASE1, PHASE2","title":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-12","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse","enrollment":439},{"nctId":"NCT06875063","phase":"PHASE1","title":"GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2026-04-30","conditions":"Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell","enrollment":45},{"nctId":"NCT07284433","phase":"PHASE1, PHASE2","title":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","status":"RECRUITING","sponsor":"AvenCell Therapeutics, Inc.","startDate":"2026-01-06","conditions":"Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse","enrollment":178},{"nctId":"NCT05442515","phase":"PHASE1, PHASE2","title":"CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-28","conditions":"B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia","enrollment":126},{"nctId":"NCT07391657","phase":"PHASE3","title":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-23","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":508},{"nctId":"NCT07461831","phase":"PHASE2","title":"CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2022-02-01","conditions":"Large B-Cell Lymphoma (LBCL)","enrollment":100},{"nctId":"NCT05535855","phase":"PHASE1","title":"UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-01-24","conditions":"Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia","enrollment":29},{"nctId":"NCT06256484","phase":"PHASE1","title":"A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Atara Biotherapeutics","startDate":"2024-09-06","conditions":"Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","enrollment":1},{"nctId":"NCT06688799","phase":"PHASE1, PHASE2","title":"Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2024-11-23","conditions":"Autoimmune Diseases","enrollment":18},{"nctId":"NCT05537766","phase":"PHASE2","title":"Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies","status":"TERMINATED","sponsor":"Kite, A Gilead Company","startDate":"2022-11-01","conditions":"Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt Lymphoma","enrollment":19},{"nctId":"NCT07304154","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases","status":"NOT_YET_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2026-03","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis","enrollment":52},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT06585514","phase":"PHASE1, PHASE2","title":"Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2024-10-17","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":18},{"nctId":"NCT06343090","phase":"NA","title":"Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2024-04-12","conditions":"B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia","enrollment":353},{"nctId":"NCT06308978","phase":"PHASE1","title":"A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","status":"RECRUITING","sponsor":"Fate Therapeutics","startDate":"2024-03-28","conditions":"Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc)","enrollment":244},{"nctId":"NCT06326008","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2026-03-15","conditions":"B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse","enrollment":48},{"nctId":"NCT04276870","phase":"PHASE2","title":"Orphan Indications for CD19 Redirected Autologous T Cells","status":"RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2020-03-12","conditions":"Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation","enrollment":133},{"nctId":"NCT07456371","phase":"PHASE1","title":"PIC1 Injection Therapy for Relapsed/Refractory B-NHL","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","startDate":"2026-03","conditions":"Non-Hodgkin Lymphoma","enrollment":18},{"nctId":"NCT07451236","phase":"PHASE1, PHASE2","title":"CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA","status":"NOT_YET_RECRUITING","sponsor":"Chang Yingjun","startDate":"2026-03-18","conditions":"Transplantation Candidates With Hematological Diseases","enrollment":18},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT06548607","phase":"EARLY_PHASE1","title":"Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases","status":"RECRUITING","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2024-09-14","conditions":"SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis","enrollment":20},{"nctId":"NCT06475495","phase":"PHASE1, PHASE2","title":"Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2024-12-04","conditions":"Rheumatoid Arthritis","enrollment":13},{"nctId":"NCT06913608","phase":"PHASE1","title":"A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases","status":"WITHDRAWN","sponsor":"Calibr, a division of Scripps Research","startDate":"2026-03","conditions":"Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)","enrollment":""},{"nctId":"NCT07073547","phase":"PHASE1","title":"A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-31","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT05801913","phase":"PHASE1","title":"Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-09-29","conditions":"High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma","enrollment":15},{"nctId":"NCT04510051","phase":"PHASE1","title":"CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-12-04","conditions":"Malignant Brain Neoplasm, Recurrent Malignant Brain Neoplasm, Refractory Malignant Brain Neoplasm","enrollment":18},{"nctId":"NCT07335562","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2026-04-30","conditions":"Systemic Sclerosis","enrollment":92},{"nctId":"NCT04661384","phase":"PHASE1","title":"Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-03-05","conditions":"Ependymoma, Glioblastoma, Medulloblastoma","enrollment":10},{"nctId":"NCT04416984","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Allogene Therapeutics","startDate":"2020-05-21","conditions":"Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma","enrollment":160},{"nctId":"NCT07188558","phase":"PHASE3","title":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","status":"RECRUITING","sponsor":"Lyell Immunopharma, Inc.","startDate":"2026-01-12","conditions":"Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma","enrollment":400},{"nctId":"NCT07115745","phase":"PHASE1","title":"A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-09-04","conditions":"Refractory Autoimmune Diseases","enrollment":125},{"nctId":"NCT06897930","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-21","conditions":"Lupus Erythematosus, Systemic","enrollment":150},{"nctId":"NCT05873712","phase":"PHASE2","title":"Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome","status":"RECRUITING","sponsor":"Aseel Alsouqi","startDate":"2023-07-28","conditions":"Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT06486051","phase":"PHASE2","title":"A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Malaghan Institute of Medical Research","startDate":"2024-07-12","conditions":"Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL)","enrollment":60},{"nctId":"NCT06947473","phase":"PHASE1, PHASE2","title":"Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2026-03-18","conditions":"Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension","enrollment":45},{"nctId":"NCT06947460","phase":"PHASE1, PHASE2","title":"CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-04-18","conditions":"Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension","enrollment":45},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT06364423","phase":"PHASE1, PHASE2","title":"Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-03","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia","enrollment":132},{"nctId":"NCT07441525","phase":"EARLY_PHASE1","title":"UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-02-03","conditions":"Autoimmune Hemolytic Anemia, Primary Immune Thrombocytopenic Purpura, Evans Syndrome","enrollment":27},{"nctId":"NCT07443137","phase":"PHASE1","title":"CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-05","conditions":"Large-cell Lymphoma","enrollment":20},{"nctId":"NCT06173518","phase":"PHASE1","title":"A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)","status":"RECRUITING","sponsor":"Autolus Limited","startDate":"2023-11-16","conditions":"Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT07078929","phase":"PHASE1","title":"Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)","status":"RECRUITING","sponsor":"Chulalongkorn University","startDate":"2026-01-01","conditions":"Relapse B Acute Lymphoblastic Leukemia, Refactory Childhood Acute Lymphoblastic Leukemia","enrollment":16},{"nctId":"NCT07444307","phase":"PHASE1","title":"A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Hangzhou Qihan Biotech Co., Ltd.","startDate":"2025-12-15","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":18},{"nctId":"NCT03939026","phase":"PHASE1","title":"Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma","status":"COMPLETED","sponsor":"Allogene Therapeutics","startDate":"2019-05-01","conditions":"Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma","enrollment":50},{"nctId":"NCT05714345","phase":"PHASE2","title":"Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy","status":"TERMINATED","sponsor":"Allogene Therapeutics","startDate":"2023-11-01","conditions":"Relapsed/Refractory Large B Cell Lymphoma","enrollment":2},{"nctId":"NCT07369492","phase":"PHASE1","title":"Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma","status":"RECRUITING","sponsor":"Jiangsu Topcel-KH Pharmaceutical Co., Ltd.","startDate":"2026-01-01","conditions":"B-cell Lymphoma","enrollment":30},{"nctId":"NCT07435779","phase":"EARLY_PHASE1","title":"Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study","status":"RECRUITING","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2026-02-04","conditions":"UC","enrollment":12},{"nctId":"NCT05757219","phase":"PHASE2","title":"Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-05-19","conditions":"Diffuse Large B Cell Lymphoma","enrollment":27},{"nctId":"NCT06138132","phase":"PHASE1","title":"A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-04-10","conditions":"Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive","enrollment":12},{"nctId":"NCT06333483","phase":"PHASE1","title":"Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Autolus Limited","startDate":"2024-02-02","conditions":"Systemic Lupus Erythematosus","enrollment":18},{"nctId":"NCT07441291","phase":"PHASE3","title":"CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-11-30","conditions":"B ALL, Allogenetic Hematopoietic Stem Cell Transplantation, MRD-positive","enrollment":70},{"nctId":"NCT06235229","phase":"PHASE1, PHASE2","title":"A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","startDate":"2023-12-26","conditions":"Multiple Myeloma","enrollment":110},{"nctId":"NCT07246096","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2026-02-20","conditions":"Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Sclerosis","enrollment":60},{"nctId":"NCT07432334","phase":"PHASE1","title":"CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2026-03-01","conditions":"Refractory Systemic Lupus Erythematosus","enrollment":8},{"nctId":"NCT07429721","phase":"EARLY_PHASE1","title":"A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-03-01","conditions":"Multiple Myeloma (MM)","enrollment":24},{"nctId":"NCT07429461","phase":"EARLY_PHASE1","title":"Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-28","conditions":"B-Cell Acute Lymphoblastic Leukemia","enrollment":16},{"nctId":"NCT06121297","phase":"PHASE1, PHASE2","title":"RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2024-02-16","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis","enrollment":28},{"nctId":"NCT05432635","phase":"PHASE1","title":"Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-01","conditions":"B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CAR-T CD19","genericName":"CAR-T CD19","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"Chimeric antigen receptor T-cell therapy targeting CD19 Used for Relapsed or refractory B-cell lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}